Pregled bibliografske jedinice broj: 725562
SIGN: a Phase II, open-label, randomized study comparing gefitanib (Iressa)with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
SIGN: a Phase II, open-label, randomized study comparing gefitanib (Iressa)with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer // 11th World Conference on Lung Cancer
Barcelona, Španjolska, 2005. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 725562 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
SIGN: a Phase II, open-label, randomized study comparing gefitanib (Iressa)with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Autori
Čufer, T ; Vrdoljak, E ;
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
11th World Conference on Lung Cancer
Mjesto i datum
Barcelona, Španjolska, 03.07.2005. - 06.07.2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
non-small-lung cancer
Sažetak
SIGN: a Phase II, open-label, randomized study comparing gefitanib (Iressa)with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Izvorni jezik
Engleski
